Phase II, open-label study of HuM195 (humanized anti-CD33 monoclonal antibody) administered to patients with acute myelogenous leukemia (AML) who are documented regimen failures (RF) of the control arm of study 195-301
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Lintuzumab (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 29 Sep 2005 New trial record.